![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly Plans a Response on Bydureon This Week, Estimates Health Reform Costs
Eli Lilly Plans a Response on Bydureon This Week, Estimates Health Reform Costs
April 20, 2010
Eli Lilly and its partners
plan to submit a response this week to the FDA’s complete response letter on once-weekly diabetes drug Bydureon. Last
month, Lilly, Alkermes and Amylin Pharmaceuticals received a complete response letter requesting final labeling information and a risk evaluation and mitigation
strategy for Bydureon (exenatide). The drug also is under review by the European Medicines Agency, the company said.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
21Oct